Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2011; 32(01): 55-56
DOI: 10.4103/0971-5851.81893
LETTERS TO EDITOR

Shorter course of trastuzumab: Caveat emptor

Ajit Venniyoor
Department of Medical Oncology, Seven Hills Hospital, Marol, Andheri (E), Mumbai - 400 059, Maharashtra, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
16 August 2021

© 2011. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: A meta-analysis of published randomized trials. BMC Cancer 2007;7:153.
  • 2 Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
  • 3 von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:1999-2006.
  • 4 Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
  • 5 Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Cancer Res 2009;69:62.
  • 6 Wildiers H, Forceville K, Paridaens R, Joensuu H. Taxanes and anthracyclines in early breast cancer: Which first? Lancet Oncol 2010;11:219-20.
  • 7 Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, et al. Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009;27:6129-34.
  • 8 Baum M. Does the act of surgery provoke activation of "latent" metastases in early breast cancer? Breast Cancer Res 2004;6:160-1.
  • 9 Sahin I, Ararat E, Altundag K. Possible mechanisms behind taxane-anthracycline sequencing. Lancet Oncol 2010;11:514-5.
  • 10 Peto R on behalf of EBCTCG. Breast Cancer Res Treat. 2007;106:P-1. Presented at San Antonio Breast Cancer Conference, 2007.
  • 11 Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S, Suter T. Anthracycline-trastuzumab regimens for HER2-neu overexpressing breast cancer: current experience and future strategies. Ann Oncol 2008; 19:1530-9.
  • 12 Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro study. J Clin Oncol 2010;28:2024-31.
  • 13 Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive breast cancer: A randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat 2010;119:95-104.
  • 14 Earl HM, Vallier A, Hiller L, Fenwick N, Iddawela M, Hughes-Davies L′ et al. Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide of E/C and paclitaxel ± gemcitabine in the treatment of high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR). J Clin Oncol 2009;27:15s.